CELZ completes enrollment and treatment in FDA-cleared ADAPT opioid trial
CELZ Creative Medical Technology Holdings says it has completed enrollment and treatment across the entire FDA-cleared ADAPT trial, including the opioid cohort, advancing celz-201/olastrocel toward RMAT evaluation and phase 3 planning.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.